SCHEMBL22650738

SCHEMBL22650738

C=C(C)c1cnn2ccc(OCc3ccccc3)cc12

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EPHB3 P54753 2/20 0.60
MAOB P27338 4/20 0.44
MAPK14 Q16539 1/20 0.40
NR4A2 P43354 1/20 0.40
ALKBH1 Q13686 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
ROCK1 Q13464 2/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
PIM1 P11309 1/20 0.39
PIM2 Q9P1W9 1/20 0.39
ACSS2 Q9NR19 1/20 0.39
SRD5A2 P31213 1/20 0.39
ALOX5 P09917 1/20 0.38
KCNH2 Q12809 2/20 0.38
MCHR1 Q99705 2/20 0.38
CYP4F2 P78329 1/20 0.38
CYP4A11 Q02928 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3611334 0.88 EPHB3 (0.66) EPHB3MAOBMAPK14NR4A2ALKBH1
SCHEMBL3614231 0.83 EPHB3 (0.66) EPHB3MAOBMAPK14NR4A2ALKBH1
SCHEMBL28634245 0.78 EPHB3 (0.56) EPHB3MAOBMAPK14NR4A2MEN1
SCHEMBL31487828 0.78 EPHB3 (0.54) EPHB3MAOBMAPK14NR4A2MEN1
SCHEMBL17311761 0.75 EPHB3 (0.57) EPHB3NR4A2ALKBH1MEN1KMT2A
SCHEMBL2878118 0.75 EPHB3 (1.00) EPHB3MEN1KMT2AROCK1NPC1
SCHEMBL15882227 0.74 EPHB3 (0.56) EPHB3ROCK1RAB9A
SCHEMBL383126 0.72 MAOB (0.60) MAOBNR4A2NPC1RAB9AALOX5
SCHEMBL10063394 0.72 MAOB (0.73) MAOBALOX5
SCHEMBL29548553 0.71 EPHB3 (0.48) EPHB3NPC1RAB9AALOX5KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4146647-B1 CDK INHIBITORS GENENTECH INC (US) 2026-04-15 EP disclosed
US-20250325544-A1 CDK INHIBITORS GENENTECH, INC. (US) 2025-10-23 US disclosed
US-20250281487-A1 CDK INHIBITORS GENENTECH, INC. (US) 2025-09-11 US disclosed
US-20250275972-A1 CDK INHIBITORS GENENTECH, INC. (US) 2025-09-04 US disclosed
US-20250275971-A1 CDK INHIBITORS GENENTECH, INC. (US) 2025-09-04 US disclosed
CN-120040446-A CDK inhibitors 基因泰克公司 2025-05-27 CN disclosed
US-12285429-B2 CDK inhibitors GENENTECH, INC. (US) 2025-04-29 US disclosed
US-20250064806-A1 CDK INHIBITORS GENENTECH, INC. 2025-02-27 US disclosed
CN-118406049-A CDK inhibitors 锐格药业公司 2024-07-30 CN disclosed
US-20240066031-A1 CDK INHIBITORS GENENTECH, INC. 2024-02-29 US disclosed
US-20240066031-A1 CDK INHIBITORS GENENTECH, INC. 2024-02-29 US disclosed
US-20240033264-A1 CDK INHIBITORS QILU REGOR THERAPEUTICS INC. (CN) 2024-02-01 US disclosed
US-20230174512-A1 CDK INHIBITORS GENENTECH, INC. 2023-06-08 US disclosed
US-20230174512-A1 CDK INHIBITORS GENENTECH, INC. 2023-06-08 US disclosed
US-20220296595-A1 CDK INHIBITORS GENENTECH, INC. 2022-09-22 US disclosed
EP-3966213-A1 CDK INHIBITORS Qilu Regor Therapeutics Inc. (CN) 2022-03-16 EP disclosed
WO-2021226140-A1 CDK INHIBITORS QILU REGOR THERAPEUTICS INC. (CN) 2021-11-11 WO disclosed
WO-2020224568-A1 CDK INHIBITORS QILU REGOR THERAPEUTICS INC. (CN) 2020-11-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250281487-A1 CDK INHIBITORS CDK6, CDK9, CDKL1 EPHB3 3899/4885MAOB 3929/4885MAPK14 238/4885
US-20240033264-A1 CDK INHIBITORS CDK9, CDKL1, CDK3 EPHB3 4059/4885MAOB 3828/4885MAPK14 196/4885
US-20240066031-A1 CDK INHIBITORS CDK9, CDKL1, CDK3 EPHB3 4059/4885MAOB 3828/4885MAPK14 196/4885
US-20250064806-A1 CDK INHIBITORS CDK9, CDK6, CDK3 EPHB3 3977/4885MAOB 4001/4885MAPK14 190/4885
US-12285429-B2 CDK inhibitors CDK9, CDK3, CDKL1 EPHB3 4033/4885MAOB 4162/4885MAPK14 200/4885
US-20250325544-A1 CDK INHIBITORS CDK6, CDK9, CDKL1 EPHB3 3899/4885MAOB 3929/4885MAPK14 238/4885
US-20250275972-A1 CDK INHIBITORS CDK9, CDK6, CDK3 EPHB3 3977/4885MAOB 4001/4885MAPK14 190/4885
US-20220296595-A1 CDK INHIBITORS CDKL1, CDK9, CDK6 EPHB3 4371/4885MAOB 3911/4885MAPK14 170/4885
US-20230174512-A1 CDK INHIBITORS CDK9, CDKL1, CDK3 EPHB3 4059/4885MAOB 3828/4885MAPK14 196/4885
US-20250275971-A1 CDK INHIBITORS CDK6, CDK9, CDKL1 EPHB3 3899/4885MAOB 3929/4885MAPK14 238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.